Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Former Mylan Executive Faces Jail After Pleading Guilty To Insider Trading

Dayakar Mallu To Forfeit $4.27m Gained From Series Of Tips

Executive Summary

A six-year Mylan employee, Dayakar Mallu, is facing up to six years in jail after pleading guilty to insider trading and tax offence charges.

You may also be interested in...



Pfizer To Merge Off-Patent Business With Mylan

Pfizer has announced plans to merge its off-patent unit with Mylan, creating a new generics and biosimilars giant in the US.

Mylan Spooks Investors With Surprise Plans For Higher 2019 Spending

Investors sold shares in Mylan after its management unexpectedly announced that it would increase sales and marketing expenses significantly in 2019 to boost growth of complex products that are now a much bigger portion of the generic and specialty drugmaker's revenue.

Mylan Gears Up To Launch US Advair Rival This Month

Mylan has revealed that its Wixela Inhub US rival to GSK’s Advair Diskus will be on the market by the end of February, acting quickly after their recent FDA approval.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB151288

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel